Skip to main navigation
  • Follow Us:
  • Grant Portal
Catalystpharma.com

Corporate Menu

  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • News & Events
    • Careers
    • Contact Us
  • Patient Focus
    • Patient Stories
      • LEMS Stories
    • Disease Information
      • LEMS
      • MuSK-MG
      • SMA
    • Patient Resources
      • Organizations
      • Event Calendar
      • Patient Engagement
  • Research & Pipeline
    • Roadmap To Success (Strategy)
    • Pipeline (clinical)
      • LEMS Clinical
      • MuSK-MG Clinical
      • SMA Clinical
    • Product
    • Business Development
    • Healthcare Professional Outreach
  • Clinical Trials
  • Responsibility
    • Corporate Giving
    • Investigator Sponsored Research
  • Investors
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Stock Information
      • Historic Stock Lookup
    • Annual Report and Proxy
    • Analyst Coverage
    • Email Alerts
Select Page
Receivables Turnover (MRQ)

Mobile Menu

  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Corporate Governance
  • Stock Information
  • Annual Report and Proxy
  • Analyst Coverage
  • Email Alerts

Receivables Turnover (MRQ)

This is the ratio of Total Revenue for the most recent interim period divided by Average Accounts Receivables. Average Receivables is the average of Accounts Receivable in the beginning and end of the interim period.

Toolkit

  • Email Alerts

  • RSS

  • Print page

  • Search

Footer Menu

  • ABOUT CATALYST
  • PATIENT FOCUS
  • RESPONSIBILITY
  • RESEARCH & PIPELINE
  • NEWS & EVENTS
  • CAREERS
  • CONTACT US
  • CLINICAL TRIALS
CONTACT
(305) 420-3200
Email Us


FOLLOW US:
facebook twitter linkedin
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy | Accessibility Statement